Regulatory T cells (Treg) play important roles in immune system homeostasis, and may also be involved in tumor immunotolerance by suppressing Th1 immune response which is involved in anti-tumor immunity. We have previously reported that immunization with attenuated activated autologous T cells leads to enhanced anti-tumor immunity and upregulated Th1 responses in vivo. However, the underlying molecular mechanisms are not well understood. Here we show that Treg function was significantly downregulated in mice that received immunization of attenuated activated autologous T cells. We found that Foxp3 expression decreased in CD4+CD25+ T cells from the immunized mice. Moreover, CD4+CD25+Foxp3+ Treg obtained from immunized mice exhibited diminished immunosuppression ability compared to those from naïve mice. Further analysis showed that the serum of immunized mice contains a high level of anti-CD25 antibody (about 30 ng/ml, p<0.01 vs controls). Consistent with a role of anti-CD25 response in the downregulation of Treg, adoptive transfer of serum from immunized mice to naïve mice led to a significant decrease in Treg population and function in recipient mice. The triggering of anti-CD25 response in immunized mice can be explained by the fact that CD25 was induced to a high level in the ConA activated autologous T cells used for immunization. Our results demonstrate for the first time that immunization with attenuated activated autologous T cells evokes anti-CD25 antibody production, which leads to impeded CD4+CD25+Foxp3+ Treg expansion and function in vivo. We suggest that dampened Treg function likely contributes to enhanced Th1 response in immunized mice and is at least part of the mechanism underlying the boosted anti-tumor immunity.
Introduction
It is well known that CD4+ T cells (also called Th1 cells) play an important role in anti-tumor immune responses [1] .
Th1 cells produce a panel of cytokines called Th1 cytokines including IFNγ and TNFα. IL-12, produced mainly by monocytes, enhances Th1 immune response [1, 2] . Through cytokine productions, Th1 cells synergize with CD8+ T cells (called CTL) in their anti-tumor function. For example, IFNγ can activate CTL, which promote tumor cell lysis by secreting perforin, granzyme B and TNFα [3, 4] . TNFα can induce dendritic cells (DC) mediated tumor antigen recognition [5, 6] . IL-12 is a key cytokine to induce Th1 cell differentiation and enhance Th1 function [7, 8] . Many reports have shown that activity of Th1 cells is downregulated in patients with malignant tumors. For example, tumor patients had lower concentrations of Th1 cytokines in serum, which may lead to low CTLmediated anti-tumor activity and dampened DC function [9] [10] [11] . Treating patients with IL-2 plus IFNγ may induce tumor regression [12, 13] . Therefore, Th1 cytokines are believed to be an effective adjuvant immunotherapy in tumor treatment [14] .
It is indicated that malignant tumor cells may induce immune tolerance by multiple mechanisms. For example, some tumors do not express major histocompatibility complex (MHC) molecules so that these tumor cells do not elicit sufficient anti-tumor immunity [15, 16] . In other cases, tumor cells fail to generate new antigen or tumor-specific antigens; and as a result they are unable to evoke immune recognition and tumor destruction because of low intrinsic immunogenicity and tumor-associated immunosuppression [17, 18] . Moreover, even when tumor cells express tumor antigens which may act as an efficient target for MHC class I-restricted responses in vivo, the immune system still fails to produce an effective anti-tumor immune response [19, 20] . The pathological interactions between cancer cells and host immune cells in the tumor microenvironment create an immunosuppressive network that promotes tumor growth, protects the tumor from immune attack and attenuates immunotherapeutic efficacy [21, 22] . All in all, malignant tumor cells may induce tolerance in the bodies bearing tumors [23] .
Tolerance is the 'holy grail' in the field of immunology and is generally divided into central tolerance and peripheral tolerance. Regulatory (or previously called suppressor) T cells (Treg) are naturally occurring or inducible lymphocytes that have been shown to downmodulate a series of immune responses. Although it is now clear that the phrase 'regulatory T cells' encompasses more than one cell type, CD4+CD25+ Foxp3+ Treg cells have received attention due to their immunosuppressive properties in vitro and in vivo [14, 24, 25] . It has been suggested that Treg are responsible for inducing and maintaining peripheral tolerance and for negative regulation of tumor immunity so that they contribute to tumor growth in mice [12, 13, 26] . Curiel et al. [27] presented evidence that human Treg have an important immunopathological role in human cancer by suppressing tumor-associated-antigen-specific T-cell immunity. Because a number of studies have demonstrated that Treg-mediated immunosuppression is one of the crucial mechanisms of tumor immune-evasion and the main obstacle of successful tumor immunotherapy [14, [27] [28] [29] , Treg depletion has been attempted in tumor therapy. While CTLA-4 blockade has been shown to enhance anti-tumor immunity [30, 31] , a number of studies have implicated that Treg depletion could be another effective strategy in tumor biotherapy. For example, Onizuka et al. [32] and Shimizu et al. [33] reported that a single in vivo administration of anti-CD25 monoclonal antibody caused the regression of tumors that grew progressively in syngeneic mice. Sutmuller et al. [34] showed that CTLA-4 blockade and Treg depletion could synergize to elicit enhanced therapeutic anti-tumor immunity.
In our previous work, we reported that administration with irradiated, activated autologous T cells in mice evokes anti-tumor immunity by enhancing the survival of activating T cells, which is accompanied by GADD45b upregulation in T cells [35] . In this report, we further investigated the anti-tumor mechanisms elicited by activated autologous T immunization. We unexpectedly found that CD4+CD25+ T cells were downregulated by our immunization procedure. This downregulated population was further identified as CD4+CD25+Foxp3+ Treg by Foxp3 staining and proliferation-inhibition assay. Interestingly, we found that downregulation of Treg after immunization was caused by anti-CD25 antibody produced in immunized mice. We thus demonstrated for first time that immunization with irradiated, activated autologous T cells could induce anti-CD25 antibody production in recipient mice, which leads to downregulation of both the population and suppressor function of Treg. We suggest that reduced Treg function induced by our immunization might relieve Th1 from suppression and allow for production of more cytokines, which in turn contributes to enhanced anti-tumor immunity in vivo.
Materials and Methods

Mice
Female C57/Bl/6 mice were purchased from the Shanghai Laboratory Animal Center, Chinese Academy of Sciences. Mice were maintained under pathogen-free conditions and used between ages of 6 and 8 weeks.
Autologous activated T-cell preparation and mice administration
Splenocytes (5×10 6 /ml) were purified and stimulated with 5 mg/ml ConA (Vector Laboratories, Burlingama, CA, USA) in complete DMEM (DMEM with 10% fetal calf serum, 10 mM HEPES, 50 mM b-mercaptoethanol, 2 mM l-glutamine and 50 IU/ml penicillinstreptomycin) in 25 ml flasks for 72 h. The cells were collected and washed three times with PBS (pH 7.4). T cells were then purified using Dynabeads coated with specific antibodies by negative selection (Dynal Biotech, Oslo, Norway). The purity of T cells obtained from culture was greater than 92%. Purified T cells were irradiated at 3 000 rad, and mice were administrated for immunization as described in our previous report [35] .
Cytokine measurement by ELISA
Sera were collected from both immunized mice and naïve mice before they were sacrificed. The serum samples were tested in 
Isolation of CD4+, CD4+CD25-, and CD4+CD25+ T cells
Fresh spleens were removed and prepared for single-cell suspensions. CD4+ T cells were negative isolated from the resulting splenocytes using magnetic bead separation. Briefly, splenocytes were depleted for CD8+, B220+, CD16+, Gr-1+ and Ly76+ cells using biotin-labeled specific mAb (BD Biosciences PharMingen, San Diego, CA, USA), anti-biotin magnetic beads, and an LD magnetic bead column (Miltenyi Biotec, Auburn, CA, USA). To isolate CD4+CD25+ or CD4+CD25-T cells, purified CD4+ T-cell populations were incubated with biotin-labeled anti-CD25 antibody (BD Biosciences) and anti-biotin magnetic beads and were isolated by MACS separation column (Miltenyi Biotec). To isolate mouse CD4+CD25-T cells, CD4+ T cells were first purified from splenocytes using a CD4+ No-touch T-cell isolation kit (Miltenyi Biotec, Auburn, CA, USA) and CD4+CD25-T cells were isolated by negative selection using CD25 microbeads (Miltenyi Biotec). The purity of CD4+, CD4+CD25+ or CD4+CD25-T-cell fractions was always greater than 95%.
Cell surface molecules and Foxp3 analysis by flow cytometry
Cells activated by ConA were used for mice immunization, and single splenocytes were obtained from immunized and naïve mice, and were stained with special goat anti-mouse CD3, CD4, CD8, CD25, CD62L and CD69 antibodies followed by flow cytometry detection. Briefly, cells were resuspended in PBS containing 1% BSA (Irvine) and 0.1% sodium azide (Sigma-Aldrich). For surface staining of CD4, CD8, CD25, CD62L and CD69, T cells were incubated with fluorochrome-conjugated antibodies to the indicated cell surface markers (eBioscience) at the recommended dilution or the isotype control antibodies for 30 min on ice. For intracellular staining of Foxp3, cells were fixed and permeablized with Foxp3 staining buffer (eBioscience). Resulting cells were stained with PE-conjugated anti-mouse Foxp3 mAb (0.5 mg/10 6 cells; eBiosceience). Stained cells were analyzed subsequently using a FACS Calibur™ (Becton Dickinson, San Jose, CA, USA).
Proliferation and inhibition assays
In proliferation assays, mouse splenocytes (2×10 5 per well) were cultured in triplicate in complete DMEM (DMEM with 10 % fetal calf serum, HEPES, b-mercaptoethanol, l-glutamine, sodium pyruvate and penicillin/streptomycin) in 96-well flat-bottomed plates. Cells were cultured in the presence or absence of ConA (5 mg/ml) at 37 °C in 5% CO 2 for 72 h. Cells were pulsed with 1 mCi [ 3 H]-thymidine during the last 16-18 h of culture before harvest. [ 3 H]-thymidine incorporation was measured as CPM using a b-plate counter. To evaluate the inhibitory activity of Treg, freshly isolated CD4+CD25-T cells from naïve mice were used as the responder. Antigen presenting cells (APCs) were obtained by isolating the positive fraction after removal of the CD4+ cells from splenocytes by magnetic sort, and were irradiated with 5 000 rad. 2×10 4 CD4+CD25-T cells were stimulated with ConA (5 mg/ml) in the presence of 1×10 5 irradiated APCs with or without the addition of CD4+CD25+ T cells (from naïve or immunized mice respectively, at the cell density of 2×10 
RNA extraction and Foxp3 expression analysis by real-time PCR
Total RNA was isolated from cell pellets using RNeasy Mini Kit (Qiagen, Hilden, Germany). Genomic DNA was removed from total RNA before cDNA synthesis using the RNase-free DNase Set for DNase digestion during RNA purification (Qiagen). RNA was stored at -80 °C. First-strand cDNA synthesis was performed for each RNA sample using Sensiscript RT Kit (Qiagen). Random hexamers (BioAsia Biotechnology, Shanghai, China) were used to prime cDNA synthesis. mRNA expression level of Foxp3 was determined by real-time PCR using SYBR Green master mix (Applied Biosystems, Foster City, CA, USA). Thermocycler conditions comprised an initial holding at 50 °C for 2 min, then 95 °C for 10 min, which was followed by a two-step PCR program consisting of 95 °C for 15 s, and 60 °C for 60 s for 40 cycles. Data were collected and quantitatively analyzed on an ABI Prism 7900 sequence detection system (Applied Biosystems). The mouse b-actin gene was used as an internal control to normalize for differences in the amount of total RNA in each sample. All quantities were expressed as number of folds relative to the expression of b-actin. PCR primer pairs were as follows: 5′-AGG AGC CGC AAG CTA AAA GC-3′ and 5′-TGC CTT CGT GCC CAC TGT-3′ for mouse FoxP3; 5′-TGT CCA CCT TCC AGC AGA TGT-3′ and 5′-AGC TCA GTA ACA GT C CGC CTA G A-3′ for mouse b-actin.
Measuring serum level of anti-mouse CD25 antibody
Sera were collected from both immunized mice and naïve mice before they were sacrificed. The serum samples were tested in duplicate for production of anti-CD25 antibody using ELISA. Briefly, microtiter plates were coated overnight at 4 °C with 50 ng/well of purified mouse CD25 protein (R&D, Minneapolis, MN, USA). After blocking at room temperature for 2 h with PBS containing 3% bovine serum albumin (BSA) (Sigma) followed by washing four times with PBS containing 0.02% Tween-20, the sera collected from mice were added. As a positive control, different amounts of a specific monoclonal anti-mouse CD25 antibody (eBioscience, USA) were added into the coated wells to generate a standard curve. The plates were incubated at 4 °C overnight followed by four additional npg washes. Then appropriate biotinylated-detecting antibody (0.25 mg/ ml) was added and incubated at RT for 2 h. Plates were washed and incubated with avidin-conjugated horseradish peroxidase at 1:2000 dilution. 0.0123% tetramethylbenzidine/0.008% H 2 O 2 in citrate buffer (pH 5.0) was used as a substrate. After 20 min incubation at room temperature, the color development was stopped using 1 M H 2 SO 4 . Optical densities were measured using an ELISA reader at 450 nm and concentrations of anti-CD25 were calculated according to the standard curve.
Serum adoptive transfer and assay for the inhibition function of Treg
Sera (0.8 ml) isolated from naïve and immunized mice respectively were transferred into naïve mice by invtravenous injection (i.v.). The CD4+CD25+ T cells in peripheral blood mononuclear cells (PBMC) of recipient mice were measured every day for 4 days after the transfer. CD4+T cells were isolated from splenocytes obtained from recipient mice as described in earlier sections. Foxp3 staining and analysis for the inhibition function of CD4+CD25+ T cells were carried out as described above.
Statistical analysis
Student's t-test was used to analyze the differences between the groups. One-way ANOVA was initially performed to determine whether an overall statistically significant change existed before using the two-tailed paired or unpaired Student's t-test. p-value of <0.05 was considered statistically significant.
Results
Enhancement of IFNγ and IL-12 production in immunized mice
As shown in our previous work, immunization with attenuated activated autologous T cells evokes anti-tumor immunity by inducing IL-12 production and CTL-mediated cytotoxicity. To analyze CD4+ T-cell function after immunization, a panel of cytokines in immunized mice was quantified and compared with those from naïve mice. The sera were collected from both immunized mice and npg naïve mice before they were sacrificed. The serum samples were tested in duplicate for the production of IFNγ, IL-12, TNFα and IL-10 using ELISA kits (R&D). In this assay, the IL-12 level was significantly increased in the immunized mice as we reported before (p = 0.0057) [35] . Th1 cytokines IFNγ and TNFα increased significantly also in immunized mice than those from naïve mice (p = 0.047 and 0.021 respectively). IL-10, a Th2 cytokine, was also increased in immunized mice but its absolute concentration (around 35 ng/ml) was lower compared with IL-12 and the two Th1 cytokines. For example, IFNγ in immunized mice was 700 ng/ml compared with 400 ng/ml in naïve mice (p<0.001). Similarly, concentration of IL-12 in immunized mice was 700 ng/ml, but in naive mice the concentration of IL-12 was 300 ng/ml (p<0.05). These results suggested that the immunization induced both IL-12 and INFγ production ( Figure 1 ), which in turn might favor Th1 response and anti-tumor immunity.
Reduced CD4+CD25+ T-cell population in immunized mice
We showed previously that immunization with attenuated activated autologous T cells triggers T-cell activation in vivo [35] . We tried to address the T-cell activation pattern induced by our immunization. CD62L was used to detect resting T-cell population and CD25 was used to detect activating T cells respectively [12] [13] [14] . For this assay, the PBMC were collected, and CD62L and CD25 on CD4+ and CD8+ T cells in PBMCs were identified by flow cytometery. The results showed that the CD62L+CD4+ T and CD62L+CD8+ T cells were lower in mice that received three times of immunization than that in naïve mice ( Figure  2A ). This result suggests that there were fewer resting T cells in the peripheral T population after immunization. Intriguingly, in this assay we unexpectedly found that within CD4+ T cells the number of CD25+ cells also did not increase, as the CD4+CD25+ T population decreased significantly in immunized mice (p = 0.019; Figure 2B ). This implicated that immunization with irradiated autologous T cells did not increase CD4+CD25+ T population. It is well known that CD25 serves as a dual marker in CD4+T cells. CD25 is expressed on activated CD4+ T cells and recently is also used as a cell surface marker for Treg. Since CD4+CD25+ T are a heterogeneous population consisting of activated CD4+ T cells and Treg, we further asked which sub-population of CD4+ T cells were diminished.
Downregulation of regulatory T-cell population in immunized mice
As we failed to detect an increase of circulated CD4+CD25+ T cells in immunized mice, we asked whether the reduced population of CD4+CD25+ T cells represent Figure  3A) . The Foxp3+ population was reduced in CD4+CD25+ T cells isolated from immunized mice compared with that in naïve mice (p = 0.0028; Figure 3B ). These results implicated that immunization with autologous activated T cells induced a drop in Treg population in vivo. To clarify whether Treg function was impaired in immunized mice, the ability of these Treg to inhibit the proliferation of CD4+CD25-T cells was studied. CD4+CD25-T cells were purified from normal naive C57 mice as responders, and CD4+CD25+ T cells derived from immunized mice and their counterparts obtained from naïve mice were used as inhibitors. Cell proliferation was measured by thymidine incorporation.
The results showed that Treg isolated from immunized mice were impaired in their ability to inhibit the proliferation of CD4+CD25-T cells, while the proliferation was inhibited by Treg from normal naive mice (p = 0.0068; Figure 3C ). These data strongly suggest that immunization with irradiated activated autologous T cells impairs the regulatory function of CD4+CD25+ Treg cells in vivo.
Immunization with autologous activated T cells induces anti-CD25 antibody in vivo
To address how and why immunization reduced the population and regulatory function of CD4+CD25+ Treg, we asked whether there was anti-CD25 production in sera from immunized mice. To test this, we first quantified B cell population with specific anti-B220 staining. The results indicated that B220 positive cells were markedly increased in immunized mice (p < 0.0001; Figure 4A ). Further IgGbinding profile was scanned with flow cytometery and the results showed that the IgG in the sera collected from immunized mice bound specifically with ConA activated autologous T cells used for immunization ( Figure 4B ). To address whether this kind of reactive IgG from immunized mice represents anti-CD25 antibody, we performed ELISA analysis. The results showed that anti-CD25 antibody was detected from immunized mice using 50 ng/ml of commercial purified mouse CD25 to coat the plates, and that the anti-CD25 antibody was dramatically increased in the sera from immunized mice. The concentration of anti-CD25 was quantitatively analyzed using the commercial purified anti-CD25 monoclonal antibody as the standard curve, and the results showed that the level of specific anti-CD25 an-
npg tibody in immunized mice was 28.3±1.8 ng/ml compared to 8.7±1.2 ng/ml in the sera collected from naïve mice (p < 0.0001; Figure 4C ). These data implicated that there were higher levels of anti-CD25 antibody induced in the immunized mice, which might be responsible for the reduced Treg population and impaired Treg function in vivo.
CD25 was dominantly expressed on activated autologous T cells used for immunization
To address how and why immunization induced anti-CD25 antibody in vivo, the kinetic expressions of CD62L, CD69 and CD25 which represent different activation stages of T cells were investigated. T cells were collected and stained by specific antibodies followed by cytometery detection at every 24 h after stimulation with ConA. The results showed that these three molecules displayed different expression pattern on the cells with different peak point. At 72 h, both CD62L and CD69 showed low expression on cell surface; even though they did increase at 48 h after stimulation by ConA, their levels dropped quickly afterwards and returned to the base line at 72 h. In contrast, CD25 expression increased continuously in a time-dependent manner when the cells were incubated with ConA ( Figure  5A ). It is worth to point out that about 70% of CD3+T cells expressed CD25 molecule while only a small portion of them expressed CD62L and CD69 at 72 h after stimulation with ConA ( Figure 5B ). This implicated that CD25 was the dominant molecule expressed on the ConA activated T cells that were used for immunization. The molecule profiles on cells used for immunization suggested that the activated autologous T cells used for immunization might bring abundant CD25 molecules into the immunized mice, and these CD25 molecules might stimulate the recipient mice to produce anti-CD25 antibody, which in turn reduces the population and function of Treg in these mice.
Adoptive transfer of sera from immunized mice resulted in Treg reduction in recipient mice
To address whether the reduction of Treg population and function in immunized mice was due to the higher level of anti-CD25 antibody induced by immunization, serum adoptive transfer assay was performed. Sera were collected from both naïve and immunized mice, and 0.8 ml of sera were injected into naïve mice by i.v. Following sera adoptive transfer, the kinetics of CD4+CD25+ T cells in PBMC from the recipient mice were measured every day for 4 days. The results demonstrated that CD4+CD25+ T cells were decreased at day 1 after sera transfer and reached the lowest level on day 2. On day 3, the CD4+CD25+ T cells recovered and returned to the original level by day 4. Compared with mice that received sera from naïve mice, CD4+CD25+ T cells were markedly reduced after receiving sera from immunized mice especially on day 2 (p = 0.03; Figure 6A ). We also analyzed Foxp3 expression in CD4+T cells in the recipient mice and examined Treg-mediated inhibition function. The results showed that Foxp3 expression was reduced in CD4+ T cells obtained from immunization sera recipients compared with those naïve sera recipients (p = 0.0037; Figure 6B) . Meanwhile, the inhibitory activity assay showed that the suppressive function of CD4+CD25+ T Treg reduced by autologous T-cell immunization 634 npg cells isolated from mice that received sera of immunized mice was significantly decreased (p = 0.0014; Figure 6C ). These data suggest that anti-CD25 antibody induced by immunization mediated Treg downregulation in vivo.
Discussion
We have previously reported that immunization with attenuated activated autologous T cells leads to enhanced T-cell survival and apoptosis resistance, which is accompanied by GADD45b upregulation in these cells. We also found that IL-12 level is increased in recipient mice. As a result, Th1 response is upregulated in vivo, and CTL activity is enhanced, leading to augmented anti-tumor immunity [35] .
Th1 cells play an important role in anti-tumor immune responses by producing a panel of cytokines such as IFNγ and TNFα [1, 2] . IL-12 enhances Th1 cell polarization, leading to more IFNγ and TNFα production. Through these cytokines, Th1 cells synergize with CTL and DC in anti-tumor immunity [4] [5] [6] [7] [8] [9] . We have shown previously that immunization with attenuated activated autologous T cells leads to more IL-12 production. Here by using a more sensitive assay kit, we showed that our immunization procedure also increases IFNγ and TNFα levels in the serum of immunized mice compared with naïve mice. Therefore, Th1 activity is enhanced by the immunization [35] .
As Th1 cells belong to the CD4+ T cells, we intended to further examine the activation status of CD4+ T cells by analyzing their surface markers, such as CD62L and CD25. CD62L is usually expressed at a high level on resting T cells [36, 37] , while CD25, the α-chain of IL-2 receptor expressed upon T-cell activation, has been used as a marker for activated T cells [38] [39] [40] . The data showed CD62L+ Tcell population was reduced (and thus CD62L low population was increased) in PBMC from immunized mice. We have shown previously that in the splenocytes, immunization actually led to an increase in CD62L+ T cells [35] . We think that this difference observed between peripheral and spleen T cells may be due to their different respective microenvironments. In anti-tumor immunity, both CD4+ CD62L low and CD8+ CD62L low T cells are believed to play important roles [41, 42] . Our data suggested that immunization with attenuated activated autologous T cells increased CD62L low T population, which is consistent with reports by other groups [41] [42] [43] . Given that CD25 is a component of IL-2 receptor which maintains T-cell proliferation and expansion after activation, and that Th1 activity is induced by our immunization, one would expect that the CD25+ population should be increased in CD4+ T cells from immunized mice. Somewhat surprisingly, the results from our experiments showed that CD25+ population actually Recently, Treg have been identified as a subset of CD4+CD25+ T cells and have been suggested to be responsible for inducing and maintaining peripheral tolerance as well as the negative regulation of tumor immunity [12] [13] [14] [24] [25] [26] . Given that our immunization induces anti-tumor immunity and decreases the CD25+ population in CD4+ T cells, we hypothesized that the Treg population might be suppressed in immunized mice. To test this hypothesis, we examined CD4+CD25+ T cells for the expression of Foxp3, a key marker for Treg. Our results showed that both the mRNA and protein levels of Foxp3 were significantly reduced in CD4+CD25+ T cells obtained from immunized mice compared with that from naïve control. Functional analysis indicated that CD4+CD25+ T cells from immunized mice exhibited a significantly lower ability to suppress the proliferation of activated T cells. These data support our hypothesis that the Treg population decreased in immunized mice. The suppressed Treg population and function likely contributed to the enhanced Th1 response in immunized mice, which in turn led to augmented antitumor immunity [26-29, 32, 33] .
To gain insight into how our immunization led to reduced Treg population and function, we found that B220+ population was significantly higher in peripheral lymphocytes from immunized mice. This implicated that B cells were expanded by the immunization in vivo. Because B cell expansion usually leads to antibody production [44, 45] , we examined the total IgG level in serum of immunized mice and found that its concentration was significantly higher (data not shown). In further analysis, we found that anti-CD25 antibody was induced to a significantly higher level in recipient mice by immunization. These results suggested that immunization with attenuated activated autologous T cells could induce anti-CD25 antibody production, which might be responsible for the observed decrease of Treg population.
To address why our immunization would stimulate the production of anti-CD25 antibody, we examined the activated autologous T cells used in immunization for their surface antigen expression, and found that CD25 was the dominantly expressed molecule on these cells. From these data, we suggest that immunization with these cells would present an abundant source of CD25 molecules, which could stimulate B cell expansion and the production of anti-CD25 antibody in vivo.
It is known that CD4+CD25+ T are a heterogeneous population consisting of activated CD4+ T cells and Treg [12] [13] [14] . To further test the hypothesis that the high level of anti-CD25 antibody in immunized mice is responsible for the impeded Treg function, serum adoptive transfer experiments were performed, where serum was isolated from immunized mice and injected i.v. into naïve recipient mice. The results demonstrated that CD4+CD25+Foxp3+ T cells in recipient mice decreased and dropped to the lowest level at day 2 after the serum transfer. Functional assays confirmed that CD4+CD25+ T cells from the recipient mice showed impeded Treg function as their ability to inhibit activated T-cell proliferation is significantly impaired.
It is well known that Treg are responsible for inducing and maintaining peripheral tolerance and the negative regulation of immunity [24, 25] . Treg have been suggested to play an important immunopathological role in human cancer by 'lowering' the intrinsic T-cell immunity towards tumor-associated antigen, resulting in tumor immune evasion [14, [27] [28] [29] . Some reports have indicated that Treg depletion can be useful in tumor biotherapy [32, 33] . Treg depletion would eliminate immune-suppression mediated by Treg leading to enhanced T-cell activity. We show here that immunization with attenuated activated autologous T cells was able to markedly decrease Treg population and function in vivo, which we think at least partially contributed to the enhanced Th1 activity and anti-tumor immunity in immunized mice. Indeed, studies in mice with tumor inoculation after the immunization showed that inhibition of tumor growth is accompanied by Treg downregulation (our unpublished data).
In conclusion, our results demonstrate for the first time that immunization with attenuated activated autologous T cells evokes anti-CD25 antibody production and leads to impeded CD4+CD25+Foxp3+ Treg function in vivo. We suggest that the dampened Treg function likely contributes to enhanced Th1 response in immunized mice and is at least part of the mechanism underlying the boosted anti-tumor immunity.
